<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00234429</url>
  </required_header>
  <id_info>
    <org_study_id>1839IL/0143</org_study_id>
    <nct_id>NCT00234429</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study of Tomudex &amp; Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Double-Blind Phase 2b Study of Raltitrexed (Tomudex) and ZD1839 (Iressa) Versus Raltitrexed Alone as Second Line Chemotherapy in Subjects With Colorectal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the activity of raltitrexed and ZD1839
      versus raltitrexed alone as second line chemotherapy in subjects with colorectal carcinoma by
      estimating progression free survival (PFS) in each treatment arm.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the progression free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine objective tumor response</measure>
  </secondary_outcome>
  <enrollment>74</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib, raltitrexed</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged 18 to 75 years, inclusive

          -  histologically-confirmed metastatic colorectal carcinoma; measurable lesion according
             to the Response Evaluation Criteria in Solid Tumours (RECIST)

          -  relapsed after treatment with a fluoropyrimidine-based chemotherapy

          -  prior chemotherapeutic regimen for metastatic or locally advanced disease with an
             interval of at least 4 weeks between the last administration of chemotherapy an the
             first administration of study treatment

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

          -  life expectancy of at least 12 weeks

        Exclusion Criteria:

          -  Known severe hypersensitivity to raltitrexed or any of the excipients of this product

          -  known severe hypersensitivity to raltitrexed or any of the excipients of this product

          -  active infection or uncontrolled diarrhoea

          -  cerebral metastasis or meningeal carcinomatosis

          -  any evidence of clinically active interstitial lung disease (patients with chronic
             stable radiographic changes who are asymptomatic need not be excluded)

          -  simultaneous antitumoral treatment

          -  radiotherapy within 2 weeks before entry into the study

          -  other co-existing malignancies or malignancies diagnosed within the last 5 years with
             the exception of basal cell carcinoma or cervical cancer in situ

          -  any unresolved chronic toxicity greater than common toxicity criteria (CTC) grade 2
             from previous anticancer therapy (except alopecia)

          -  significant clinical disorder or laboratory finding (leukocyte count less than 3.0 x
             109 /litre (L) or platelets less than 100 x 109 /L; serum total bilirubin more than
             2.0 mg/dl; as judged by investigator, any evidence of severe or uncontrolled systemic
             disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic, or renal
             disease); creatinine clearance â‰¥ 65ml/min (according to Cockcroft-Gault formula);
             alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 2
             times the upper limit of the reference range (ULRR) if no demonstrable liver
             metastases, or greater than 5 times the ULRR in the presence of liver metastases)

          -  pregnancy or breast feeding (women of child-bearing potential)

          -  concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates, or ST John's
             Wort;

          -  Treatment with a non- approved or investigational drug within 30 days before Day 1 of
             study treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca Spain Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>A Coruna</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Burgos</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gijon</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leon</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valladolid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2005</study_first_submitted>
  <study_first_submitted_qc>October 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2005</study_first_posted>
  <last_update_submitted>December 14, 2007</last_update_submitted>
  <last_update_submitted_qc>December 14, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2007</last_update_posted>
  <keyword>Colorectal carcinoma advanced disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Raltitrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

